Streetbeat News

Price Targets

RVPH

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Reviva Pharmaceuticals (NASDAQ:RVPH) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 10:44 am

GVP

HC Wainwright & Co. analyst Sameer Joshi has reiterated a 'Buy' rating on GSE Systems (NASDAQ:GVP) and maintained a $3 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 10:43 am

ITRN

Barclays analyst Tavy Rosner maintains an Overweight rating on Ituran Location & Control (NASDAQ:ITRN) and raises the price target from $30 to $35.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 10:42 am

NVDA

Piper Sandler analyst Harsh Kumar maintains an Overweight rating on NVIDIA and raises the price target from $450 to $500.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 10:41 am

GRTX

HC Wainwright & Co. analyst Raghuram Selvaraju has downgraded Galera Therapeutics (NASDAQ:GRTX) from Buy to Neutral and lowered the price target from $6 to $0.3.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 10:40 am

LI

B of A Securities analyst Ming Hsun Lee maintains a Buy rating on Li Auto (NASDAQ:LI) and raises the price target from $56 to $60.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 10:39 am

UNCY

HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Unicycive Therapeutics (NASDAQ:UNCY) but has lowered the price target from $7 to $4.5.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 10:39 am

SE

B of A Securities analyst Sachin Salgaonkar maintains a Neutral rating on Sea (NYSE:SE) and lowers the price target from $73 to $53.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 10:39 am

FTI

Citigroup analyst Scott Gruber maintains a Buy rating on TechnipFMC (NYSE:FTI) and raises the price target from $22 to $25.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 10:38 am

PHIO

HC Wainwright & Co. analyst Vernon Bernardino has reiterated a 'Buy' rating on Phio Pharma (NASDAQ:PHIO) and maintained a $6 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 10:37 am